| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Dec 24, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $39.91 | $1,995,725.00 | +1.5% | |
| Dec 21, 2018 | AYTU Aytu Biopharma, Inc | Green David A | Chief Financial Officer | Sell | 3,330 | $0.81 | $2,710.95 | -1.2% | |
| Dec 20, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,910 | $3.66 | $677,107.66 | -0.5% | |
| Dec 18, 2018 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 20,488 | $7.58 | $155,299.04 | -88.3% | |
| Dec 18, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 258,127 | $3.69 | $953,384.90 | -8.1% | |
| Dec 17, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $18.18 | $454,490.85 | -3.8% | |
| Dec 17, 2018 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 60,000 | $47.73 | $2,864,070.00 | +1.8% | |
| Dec 14, 2018 | JNJ Johnson & Johnson | Perez William D | Director | Buy | 1,000 | $133.91 | $133,910.00 | +12.3% | |
| Dec 14, 2018 | BHC Bausch Health Companies Inc. | Appio Thomas | Pres&Co-head Bausch&Lomb/ Int'l | Buy | 25,440 | $22.96 | $584,018.45 | +24.6% | |
| Dec 14, 2018 | AVDL Avadel Pharmaceuticals Plc | Kanan Michael F | See Remarks | Sell | 8,429 | $2.49 | $21,021.93 | -22.2% | |
| Dec 14, 2018 | JNJ Johnson & Johnson | Prince Charles | Director | Buy | 2,000 | $134.37 | $268,731.20 | +7.5% | |
| Dec 14, 2018 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 5,000 | $2.78 | $13,883.00 | +10.6% | |
| Dec 14, 2018 | AVDL Avadel Pharmaceuticals Plc | Hatten Sandra L | See Remarks | Sell | 3,173 | $2.58 | $8,183.17 | -7.2% | |
| Dec 14, 2018 | AVDL Avadel Pharmaceuticals Plc | Gusky David P | Controller &CAO | Sell | 617 | $2.68 | $1,655.66 | -13.1% | |
| Dec 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 1,616 | $20.65 | $33,370.40 | -4.6% | |
| Dec 14, 2018 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 3,610 | $2.78 | $10,023.53 | +7.1% | |
| Dec 14, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO, President, Secretary | Buy | 2,000 | $4.38 | $8,766.00 | +9.9% | |
| Dec 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 43,577 | $20.48 | $892,308.80 | -2.1% | |
| Dec 14, 2018 | JNJ Johnson & Johnson | Mulcahy Anne M | Director | Buy | 748 | $133.76 | $100,049.94 | +12.9% | |
| Dec 13, 2018 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 3,643 | $147.31 | $536,637.58 | -21.1% | |
| Dec 13, 2018 | PCRX Pacira Biosciences, Inc. | Wicki Andreas71 | Director | Sell | 14,527 | $46.84 | $680,495.61 | -0.8% | |
| Dec 13, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 183,310 | $4.15 | $760,537.89 | -1.4% | |
| Dec 13, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Applied Physics & Chemistry Laboratories, Inc. | 10% Owner | Sell | 133,915 | $21.29 | $2,851,052.30 | -0.5% | |
| Dec 13, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 133,915 | $21.29 | $2,851,052.30 | -0.5% | |
| Dec 12, 2018 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 10,000 | $2.99 | $29,890.00 | +24.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.